Clinical trial · Interventional
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)
NCT03819465CI-TRIAL-00111231MAGELLANactive not recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Non-Small Cell Lung Cancer (NSCLC) | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AZD2936 | Drug | — | UNRESOLVED |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Danvatirsen | Drug | — | UNRESOLVED |
| Durvalumab | Drug | Durvalumab | ALIAS |
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| MEDI5752 | Drug | — | UNRESOLVED |
| Nab-paclitaxel | Drug | Nab-paclitaxel | ALIAS |
| Oleclumab | Drug |
Design
Arms and outcomes
Arms (10)
- type
- EXPERIMENTAL
- label
- A1
- description
- Durvalumab
- interventionNames
- Drug: Durvalumab
- type
- EXPERIMENTAL
- label
- A2
- description
- Durvalumab + danvatirsen
- interventionNames
- Drug: Durvalumab
- Drug: Danvatirsen
- type
- EXPERIMENTAL
- label
- A3
- description
- Durvalumab + oleclumab
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 130 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation * No prior chemotherapy or any other systemic therapy for metastatic NSCLC * Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred \>12 months from end of last therapy * Known tumor PD-L1 status * Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care * WHO/ECOG status at 0 or 1 at enrollment * Life expectancy of at least 12 weeks * Troponin I or T ≤ ULN (per institutional guidelines) Exclusion Criteria: * Active or prior documented autoimmune or inflammatory disorders * History of active primary immunodeficiency * Any prior chemotherapy or any other systemic therapy for metastatic NSCLC * Untreated CNS metastases
References
Publications (1)
- DERIVEDCho BC, Charoentum C, Kim DW, Yang CT, Dziadziuszko R, Geater SL, Mann H, Afshar-Imani B, Lyfar P, Yang JC, Patel SP. MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naive metastatic non-small-cell lung cancer. Lung Cancer. 2026 Jan;211:108834. doi: 10.1016/j.lungcan.2025.108834. Epub 2025 Nov 7. PMID 41380462